Covaxin: The first participant has been enrolled in Phase I clinical trial of GB19 injection.

Kexing Pharmaceuticals announced that its wholly-owned subsidiary, Shenzhen Kexing, has successfully completed the first dosing of participants in the Phase I clinical study of the independently developed "GB19 Injection". The drug targets the BDCA2 receptor with a significantly different mechanism of action compared to existing drugs. Preclinical studies have shown good activity and immunogenicity, and if successfully developed, it may provide a new option for patients with autoimmune diseases. The entry of participants in this study has no significant impact on the company's recent financial and performance, there are uncertainties in the follow-up research, and the company will continue to advance the project and disclose progress in a timely manner.